Verona Pharma

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Verona Pharma excels in COPD trials, secures funding for growth

Verona Pharma's strong performance in Phase 3 trials and solid financial position set a positive trajectory for future growth and NDA submission.
While facing competition and addressing various challenges, the company's strategic vision and upcoming milestones offer opportunities for expansion and partnerships.

Verona Pharma reports strong Q1 earnings, gears up for ensifentrine launch

Verona Pharma's Q1 2023 earnings call highlighted strong financial performance, progress towards NDA submission for ensifentrine, and strategic initiatives for the upcoming launch.
Despite facing challenges in managing expenses and navigating regulatory processes, the company remains optimistic about its market positioning and growth prospects.
With a focus on differentiation, global partnerships, and commercial readiness, Verona Pharma is poised for success in the COPD treatment market in 2024 and beyond.
The company's emphasis on marketing, operational setup, and post-ENHANCE data promotion underscores its commitment to maximizing market impact and revenue potential.

Verona Pharma advances ensifentrine with strong Q2 performance and global expansion prospects

Verona Pharma's Q2 2023 performance showcased progress on ensifentrine and a strong financial position, despite a net loss driven by ongoing expenses.
Strengths include positive trial results, a robust cash position, and global expansion efforts, while challenges lie in financial management and regulatory uncertainties.
Opportunities abound in FDA approval prospects, market expansion through subgroup usage, reimbursement optimization, and product portfolio expansion.
Analysts' inquiries highlighted key concerns and strategic considerations for Verona Pharma's future growth and commercial success in the COPD treatment market.

Verona Pharma advances towards FDA approval with strong financials

Verona Pharma progresses towards FDA approval for ensifentrine, with a set action date.
Financially stable with cash reserves and plans for a robust sales force.
Balancing R&D investments with increased expenses and strategic challenges.
Positioned for growth with pipeline expansion and positive data on treatment impact.

Verona Pharma excels in Q4, eyes FDA approval for ensifentrine

Verona Pharma's Q4 2023 earnings call highlighted strong financials, progress with ensifentrine's FDA submission, and strategic plans for commercial launch and market positioning. While facing challenges in FDA review and commercial strategy, the company remains optimistic about ensifentrine's market prospects and growth opportunities.

Verona Pharma excels in Q1 with ensifentrine progress and financial strength

Verona Pharma's Q1 2024 performance highlighted progress on ensifentrine, strong commercial launch preparations, and a robust financial position.
Strengths lie in ensifentrine's novelty, disease awareness focus, and the company's solid financial foundation.
Challenges include addressing analyst queries, market competition, and ensuring a successful commercial launch.
Opportunities abound in leveraging ensifentrine's utility, financial strength, and the potential for market disruption in COPD treatment.

Verona Pharma reports strong Ohtuvayre sales but faces challenges

Verona Pharma's Q3 2024 earnings call highlighted strong net product sales for Ohtuvayre, but also revealed a net loss after tax. The company's successful launch of Ohtuvayre and progress in new trials and partnerships demonstrate potential for growth. However, Verona Pharma faces challenges in addressing various aspects of its business and potential competition in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

The consensus price target hints at a 95.5% upside potential for Verona Pharma PLC American Depositary Share (VRNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 95% Upside in Verona Pharma PLC American Depositary Share (VRNA): Can the Stock Really Move This High?

The mean of analysts' price targets for Verona Pharma PLC American Depositary Share (VRNA) points to a 109.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Verona Pharma PLC American Depositary Share (VRNA)? Wall Street Analysts Think 110%

Verona Pharma plc (NASDAQ:VRNA ) Q3 2022 Earnings Conference Call November 9, 2022 9:00 AM ET Company Participants David Zaccardelli – Chief Executive Officer Mark Hahn – Chief Financial Officer Kathy Rickard – Chief Medical Officer Chris Martin – Senior Vice President-Commercial Conference Call Participants Suji Jeong – Jefferies Boobalan Pachaiyappan – H.C. Wainwright Tom Shrader – BTIG Operator Welcome to Verona Pharma's, Third Quarter 2022 Financial Results and Operating Highlights Conference Call.

Verona Pharma plc (VRNA) Q3 2022 Earnings Call Transcript

Access to up to $400 million expected to provide cash runway through at least 2025

Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update

LONDON and RALEIGH, N.C., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will participate in the following conferences in November 2022:

Verona Pharma Announces November 2022 Investor Conference Participation

Assertio Therapeutics Inc

ProPhase Labs

This year's bear markets have resulted in a fall in portfolio performance. Healthcare, the second best sector this year, is defensive and has stood the test of time. The Fed's stance and volatile price swings that include declines of more than 20% in the major indexes are prompting investors to consider defensive investments.

3 Small-Cap Pharma Stocks For A 2022 Melt-Up

LONDON and RALEIGH, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the third quarter ended September 30, 2022 on Wednesday, November 9, 2022 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update

Non-dilutive capital finances planned launch of ensifentrine for COPD Non-dilutive capital finances planned launch of ensifentrine for COPD

Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance

LONDON and RALEIGH, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces additional exacerbation* subgroup analyses from the Phase 3 ENHANCE-2 (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) trial in chronic obstructive pulmonary disease (“COPD”). Top-line results from the trial are available on Verona Pharma's website here.

Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD

Aerie Pharmaceuticals

Belite Bio Inc

Chemocentryx

Catalyst Pharmaceuticals

Akero Therapeutics Inc

Gossamer Bio Inc

Relmada Therapeutics Inc

Viridian Therapeutics

Ventyx Biosciences

The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best. The post Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year appeared first on Investor's Business Daily.

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year

Verona achieved primary and secondary endpoints in phase 3 ENHANCE-2 study using ensifentrine as maintenance treatment of COPD. Results from the second phase 3 study, ENHANCE-1, also using ensifentrine as maintenance treatment of COPD is expected by end of 2022.

Verona: Expected End Of 2022 Catalyst Could Provide Value Inflection Point

LONDON and RALEIGH, N.C., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 2:00 PM ET / 7:00 PM BST.

Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

LONDON and RALEIGH, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, continues its preparation for commercialization with appointments of Matthew Casbon, Vice President of Sales, Marketing and Training, and Matthew Rysavy, Vice President of Market Access and Trade. They each bring approximately 25 years of commercialization expertise spanning marketing, sales, training, market access, trade and business development across a variety of therapeutic areas.

Verona Pharma strengthens commercialization leadership team

LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development partner, Nuance Pharma, has received clearance from the Center of Drug Evaluation (“CDE”) for its Investigational New Drug (“IND”) application to conduct both Phase 1 and Phase 3 studies with ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”) in mainland China.

Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China

LONDON and RALEIGH, N.C., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announced today the closing of its upsized public offering of 14,260,000 American Depositary Shares (“ADSs”), each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share, at a price to the public of $10.50 per ADS, which includes the exercise in full by the underwriters of their option to purchase an additional 1,860,000 ADSs. The aggregate gross proceeds from the offering were approximately $150 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Verona Pharma. All ADSs in the offering were offered by Verona Pharma.

Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional ADSs

LONDON and RALEIGH, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announced today the pricing of its upsized public offering of 12,400,000 American Depositary Shares (“ADSs”), each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share, at a price of $10.50 per ADS, for aggregate gross proceeds of $130.2 million before deducting underwriting discounts and commissions (the “Offering”). All ADSs in the Offering are being offered by Verona Pharma. In addition, Verona Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,860,000 ADSs at the public offering price, less the underwriting discount and commission. The Offering is expected to close on August 15, 2022, subject to the satisfaction of customary closing conditions.

Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering

LONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announced a proposed underwritten public offering of 10 million American Depositary Shares (“ADSs”), each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share (the “Offering”). All ADSs in the Offering will be offered by Verona Pharma. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering. In addition, Verona Pharma intends to grant the underwriters of the Offering a 30-day option to purchase up to an additional 1.5 million ADSs at the public offering price, less the underwriting discount and commission.

Verona Pharma plc Announces Proposed Underwritten Public Offering

Verona Pharma PLC American Depositary Share (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Verona Pharma PLC American Depositary Share (VRNA) Rating Upgrade to Strong Buy

The company reported overwhelmingly positive results from a late-stage study of its COPD drug candidate.

Why Verona Pharma Stock Is Skyrocketing Today

Source: Shutterstock Verona Pharma (NASDAQ: VRNA ) stock is rocketing higher on Tuesday following the release of its latest earnings report and clinical trial results. Starting with that earnings report, the biopharmaceutical company posted earnings per share of -4 cents.

Why Is Verona Pharma (VRNA) Stock Up 76% Today?

Ensifentrine met primary and secondary endpoints of evaluating lung function in Phase 3 ENHANCE-2 trial for COPD

Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Statistically significant improvements in key measures of lung function

Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD

Second quarter 2022 financial results and corporate update Second quarter 2022 financial results and corporate update

Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial of Nebulized Ensifentrine for COPD

Verona Pharma PLC American Depositary Share (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Verona Pharma PLC American Depositary Share (VRNA) is on the Move, Here's Why the Trend Could be Sustainable

The consensus price target hints at a 283.3% upside potential for Verona Pharma PLC American Depositary Share (VRNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

News for Verona Pharma Stock (VRNA)